Nodthera Ltd.

Nodthera Ltd.

Overview

Nodthera Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) pathway for the treatment of chronic inflammatory and neurodegenerative diseases. The company was founded in 2017 and is headquartered in London, UK with operations in Cambridge, Massachusetts[@nodthera].

Nodthera's mission is to develop first-in-class small molecule inhibitors of NLRP3, a key protein complex that drives chronic inflammation in numerous diseases including Alzheimer's disease, Parkinson's disease, and inflammatory disorders.

Pipeline

Alzheimer's Disease

| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| NT-0796 | NLRP3 inflammasome inhibitor | Phase 1/2 | Recruiting |
| NT-0249 | NLRP3 inflammasome inhibitor | Preclinical | IND-enabling |

NT-0796

NT-0796 is a potent, oral, brain-penetrant NLRP3 inflammasome inhibitor being developed for the treatment of Alzheimer's disease. It represents a novel approach targeting neuroinflammation, which is increasingly recognized as a central driver of neurodegenerative processes[@nlrp].

The NLRP3 inflammasome is a multi-protein complex that activates pro-inflammatory cytokines (IL-1β, IL-18) in response to various damage-associated molecular patterns (DAMPs). In Alzheimer's disease:

Nodthera Ltd.

Overview

Nodthera Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) pathway for the treatment of chronic inflammatory and neurodegenerative diseases. The company was founded in 2017 and is headquartered in London, UK with operations in Cambridge, Massachusetts[@nodthera].

Nodthera's mission is to develop first-in-class small molecule inhibitors of NLRP3, a key protein complex that drives chronic inflammation in numerous diseases including Alzheimer's disease, Parkinson's disease, and inflammatory disorders.

Pipeline

Alzheimer's Disease

| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| NT-0796 | NLRP3 inflammasome inhibitor | Phase 1/2 | Recruiting |
| NT-0249 | NLRP3 inflammasome inhibitor | Preclinical | IND-enabling |

NT-0796

NT-0796 is a potent, oral, brain-penetrant NLRP3 inflammasome inhibitor being developed for the treatment of Alzheimer's disease. It represents a novel approach targeting neuroinflammation, which is increasingly recognized as a central driver of neurodegenerative processes[@nlrp].

The NLRP3 inflammasome is a multi-protein complex that activates pro-inflammatory cytokines (IL-1β, IL-18) in response to various damage-associated molecular patterns (DAMPs). In Alzheimer's disease:

• [Aβ](/proteins/amyloid-beta) oligomers and plaques activate NLRP3
• This leads to chronic neuroinflammation
• Inflammatory cytokines accelerate [tau](/proteins/tau) pathology
• [Microglia](/cell-types/microglia)l activation becomes dysregulated

Parkinson's Disease

Nodthera is also developing NLRP3 inhibitors for Parkinson's disease, where neuroinflammation similarly plays a critical role in disease progression.

Science

NLRP3 Inflammasome Biology

The NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome is one of several inflammasome complexes in the body. It is activated by:

Activation leads to:

• Caspase-1 activation
• Cleavage of pro-IL-1β and pro-IL-18 to active forms
• Pyroptosis (inflammatory cell death)
• Release of inflammatory mediators

• Sustained pro-inflammatory cytokine release
• Impaired Aβ clearance
• Synaptic dysfunction
• Neuronal loss

Targeting NLRP3

Nodthera's approach involves direct inhibition of NLRP3 ATPase activity, which is required for inflammasome assembly and activation. This mechanism differs from:

• Anti-IL-1β antibodies (target downstream cytokine)
• Anti-inflammatory drugs (broad effects)
• Other approaches targeting individual inflammatory pathways

Intellectual Property

Nodthera has built a strong patent portfolio around:

• Novel NLRP3 inhibitor chemotypes
• Brain-penetrant formulations
• Specific disease indications

Business Development

• Partnerships: Collaborations with leading academic institutions
• Funding: Raised over $120M in venture funding
• Investors: Leading life sciences venture capital firms

Competitive Landscape

Nodthera's NLRP3 inhibitor approach competes with:

| Company | Drug | Stage | Notes |
|---------|------|-------|-------|
| Nodthera | NT-0796 | Phase 1/2 | Brain-penetrant |
| Ionis | IONIS-MAPTRx | Phase 1/2 | Anti-tau ASO |
| INmune Bio | XPro1595 | Phase 2 | TNF inhibitor |
| AL002 (Alector) | [TREM2](/proteins/trem2) agonist | Phase 2 | Microglial target |

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation in AD](/mechanisms/neuroinflammation)
• [Microglia and Neuroinflammation](/cell-types/microglia)
• [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References